Zabrze, Poland: The transdermal application of plant-derived CBD reduces fascial pain in patients with temporomandibular disorders (TMD aka TMJ), according to clinical data published in the Journal of Clinical Medicine.

Polish investigators conducted a randomized, double-blind placebo-controlled trial assessing the efficacy of twice-daily transdermal CBD administration on 60 patients with TMD over a period of 14 days.

Compared to placebo, patients receiving CBD therapy experienced symptomatic improvements, including reduced myofascial pain severity and decreased masseter muscle (the muscle around the jaw) activity. Subjects receiving treatment reported no adverse effects.

Authors concluded, "Further research is needed in this field, but CBD, as an alternative to THC, should be taken into consideration in the therapy of masticatory muscles in patients with TMD."

Full text of the study, "Myorelaxant effect of transdermal cannabidiol application in patients with TMD: A randomized, double-blind trial," appears in the Journal of Clinical Medicine.

Share this: Twitter

Facebook

